The results showed that three synthesized compounds (4a-c) exhibited very good inhibitory potency, with IC50 ranged from 1.70 - 6.24 µM; notably, compound 4a displayed similar potency to that of Vorinostat (SAHA), a commercial drug currently used in the management of cutaneous T cell lymphoma.